Anti-CD4 monoclonal antibody therapy

Area of Science:

• Immunology
• Transplantation Medicine
• Biotechnology

Background:

• Monoclonal antibodies (mAbs) offer targeted immune response modulation.
• Anti-CD4 mAbs are investigated for their potential to induce donor-specific non-responsiveness in transplantation.
• Early clinical trials with murine anti-CD4 mAbs showed mixed results regarding efficacy and rejection episodes.

Purpose of the Study:

• To review the clinical potential and challenges of anti-CD4 monoclonal antibodies (mAbs) in transplantation.
• To evaluate the efficacy and safety of various anti-CD4 mAb preparations, including murine and humanized forms.
• To assess the role of anti-CD4 mAbs in preventing allograft rejection and inducing tolerance.

Main Methods:

• Review of preclinical and clinical studies involving anti-CD4 mAbs.
• Analysis of outcomes from trials using murine anti-CD4 mAbs (e.g., BL4, mT-151, OKT4A, Max. 16H5).
• Evaluation of humanized anti-CD4 mAb preparations (e.g., cMT-412, OKTcdr4a) in allograft recipients.

Main Results:

• Early murine anti-CD4 mAbs had high rates of rejection episodes.
• OKT4A showed improved tolerability and reduced rejection rates in limited clinical trials.
• Humanized anti-CD4 mAbs like cMT-412 and OKTcdr4a demonstrated reduced rejection frequency, delayed episodes, and improved survival in heart, heart-lung, and renal allograft recipients.
• OKTcdr4a showed no antibody response and no allograft failures in a pilot renal transplant study.

Conclusions:

• Anti-CD4 mAbs hold significant promise for specific immunosuppression in transplantation.
• Humanized anti-CD4 mAbs represent advancements over earlier murine preparations, offering better safety and efficacy profiles.
• Despite challenges in protocol optimization, anti-CD4 mAbs are likely to be crucial in future immunosuppressive strategies, especially for inducing tolerance.